Table 1.
BMI distribution of the investigated subgroups in five patient cohorts
| Total number of patients | Median (range) | Lean (%) | Overweight (%) | Obese (%) | ||
|---|---|---|---|---|---|---|
| METABRIC | NST ER+/HER2− | 215 |
26.17 (18.55, 46.41) |
86 (40.0) | 73 (34.0) | 56 (26.0) |
| NST ER−/HER2− | 68 |
25.78 (20.47, 43.46) |
30 (44.1) | 24 (35.3) | 14 (20.6) | |
| ICGC | NST ER+/HER2− | 177 |
26.00 (18.70, 51.80) |
67 (37.9) | 64 (36.2) | 46 (26.0) |
| NST ER−/HER2− | 84 |
26.00 (18.60, 55.40) |
36 (42.9) | 30 (35.7) | 18 (21.4) | |
| ELBC | ILC ER+/HER2− | 545 |
23.34 (18.51, 40.86) |
351 (64.4) | 143 (25.2) | 51 (9.4) |
| MINDACT | NST ER+/HER2− | 735 |
25.24 (18.59, 68.68) |
354 (48.2) | 250 (34.0) | 131 (17.8) |
| NST ER−/HER2− | 118 |
25.28 (19.00, 39.88) |
53 (44.9) | 54 (45.8) | 11 (9.3) | |
| ILC ER+/HER2− | 104 |
24.19 (19.27, 37.05) |
65 (62.5) | 32 (30.8) | 7 (6.7) | |
| Biokey | NST ER+/HER2− | 13 |
24.79 (19.72, 44.08) |
6 (46.2) | 3 (23.1) | 4 (30.8) |
| NST ER−/HER2− | 12 |
24.13 (22.6, 32.05) |
8 (66.7) | 2 (16.7) | 2 (16.7) |
Subgroups were determined by histological subtype, and the ER and HER2 status. Only cases with available molecular profiling data, either genomic profiling, bulk, or single-cell transcriptomic profiling, were included.